- Lexaria’s human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company’s DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, including higher pleasurable effects and reduced negative effects
- A new patent has been granted to Lexaria and is strategically important to the company’s oral nicotine sector research and development efforts
- Lexaria continues to research diabetes control and weight loss with its DehydraTECH(TM)-CBD, announcing favorable animal study results and the intent to develop a human clinical study
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced updates regarding its patented DehydraTECH(TM) technology – which improves the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. Lexaria’s primary focus for DehydraTECH research and development includes advancements of product candidates across key segments, including nicotine replacement, diabetes control and weight loss, and hypertension.
The company’s most recent announcement reported results from its 2023 human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-Nicotine tobacco-free pouch to world-leading brands ZYN(R) and on!. Using measurements to determine the median time required to reach comparable nicotine concentrations within the bloodstream (“Tmax”), Lexaria exhibited higher levels of certain pleasurable effects over the competition. DehydraTECH also provided the lowest frequency of unwanted negative effects, including moderate to severe nausea, demonstrating benefits from Lexaria’s formulation.
In addition to the announcement of favorable results from its NIC-H22-1 study, the company was recently granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office, US Patent #11,700,875 Compositions and Methods for Sublingual Delivery of Nicotine. This new patent builds upon the company’s growing portfolio of 35 granted patents, with several more pending worldwide – spanning Lexaria’s research and development focus.
“We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates advantages of DehydraTECH processed nicotine relative to the competitive landscape,” said Chris Bunka, CEO of Lexaria (https://ibn.fm/nrgGY).
Separately, Lexaria also intends to conduct a human clinical study to examine its DehydraTECH-CBD formulation for diabetes control and weight loss. This intent comes after positive results were released in early August regarding its DIAB-A22-1 study in obese diabetic-conditioned animals, which achieved the following:
- Lowered blood glucose levels by 19.9% (p<0.05)
- Lowered overall body weight by 7% sustained over eight weeks
- Witnessed a statistically significant increase in locomotor activity (p<0.05)
- Lowered triglyceride levels by more than 25% (p<0.007)
- Lowered blood urea nitrogen levels by 27.9% (p<0.001)
These successful pre-clinical results have the company determined to undertake a human study to investigate whether these improvements are also evidenced in humans. The study design is currently underway and will be submitted to an independent review board for approval.
As the company continues to grow and explore maximizing the potential of its DehydraTECH technology, a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”) has been formed. LEXX Nutra has been granted an exclusive, perpetual license entitling it to use DehydraTECH, or sublicense the use of DehydraTECH, to create consumer packaged goods and/or intermediate ingredients composed of any molecule except those associated with cannabis or nicotine. LEXX Nutra is also prohibited from using its licensing to manufacture any pharmaceutical product.
Lexaria Pharmaceutical Corp.’s licensing was also amended, ensuring it would only focus on manufacturing pharmaceutical products–excluding nicotine-associated molecules. The formation of Lexaria’s wholly-owned subsidiaries draws a distinct line in the sand for Lexaria, ensuring that proper research and development efforts for key indications are being diverted to the appropriate subsidiary.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com